EUVIMEDDécouvrir EUVIMED
Crossref

Diagnostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging in pediatric opsoclonus myoclonus ataxia syndrome presenting with neuroblastoma

Lijuan Feng iD, Shen Yang, Yu Lin, Jiuwei Li, Zhenhua Cao, Qipeng Zheng, Huanmin Wang, Jigang Yang iD

Pediatric Radiology · 2024

DOI: 10.1007/s00247-024-05921-9 ↗

At a glance

Journal article in Pediatric Radiology, 2024. Written by Lijuan Feng and 7 co-authors. Institution: Department of Nuclear Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China. Major MEDLINE topics: Neuroblastoma, Positron Emission Tomography Computed Tomography, Opsoclonus-Myoclonus Syndrome, Fluorodeoxyglucose F18. Cited 2 times so far (Crossref); 28 references. Funded by: National Natural Science Foundation of China.

RésuméSubjectsRéférences bibliographiquesCiteRelated studies

Abstract (original language)

BACKGROUND: Early precision diagnosis and effective treatment of opsoclonus myoclonus ataxia syndrome (OMAS) patients presenting with neuroblastoma can prevent serious neurological outcomes. OBJECTIVE: To assess the diagnostic value of 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) imaging in pediatric OMAS with neuroblastoma. MATERIALS AND METHODS: A retrospective evaluation of 45 patients diagnosed with OMAS who underwent 18F-FDG PET/CT was performed. A univariate analysis was performed to compare clinical characteristics between OMAS with and without neuroblastoma. Univariate and multivariate logistic regression analyses were applied to identify independent risk factors for OMAS with neuroblastoma and to develop the clinical model. Finally, independent risk factors and PET/CT were fitted to build the combined model for the diagnosis of OMAS with neuroblastoma and presented as a nomogram. Receiver operating characteristic curve, decision curve, and calibration curve analyses were conducted to evaluate the performance of the models. RESULTS: Among 45 patients, 27 were PET/CT-positive, 23/27 lesions were neuroblastoma, and four were false positives. One of the false positive patients was confirmed to be adrenal reactive hyperplasia by postoperative pathology, and the symptoms of OMAS disappeared in the remaining three cases during clinical follow-up. The average maximal standardized uptake value of PET/CT-positive lesions was 2.6. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of PET/CT were 100%, 81.8%, 85.2%, 100%, and 91.1%, respectively. Age at diagnosis, lactate dehydrogenase, and neuron-specific enolase showed statistically significant differences between OMAS with and without neuroblastoma. Lactate dehydrogenase was identified as the independent risk factor to develop the clinical model, and the clinical model demonstrated an area under the curve (AUC) of 0.82 for the diagnosis of OMAS with neuroblastoma, with an AUC as high as 0.91 when combined with PET/CT. The decision curve analysis and calibration curve demonstrated that the nomogram had good consistency and clinical usefulness. CONCLUSION: In patients with OMAS, 18F-FDG PET/CT has a high diagnostic accuracy in detecting tumors of the neuroblastoma, especially when combined with the independent risk factor serum lactate dehydrogenase.

Subjects

MeSH terms (MEDLINE)

NeuroblastomaPositron Emission Tomography Computed TomographyOpsoclonus-Myoclonus SyndromeFluorodeoxyglucose F18RadiopharmaceuticalsHumansFemaleMaleRetrospective StudiesChild, PreschoolChildInfantSensitivity and SpecificityDiagnosis, Differential

Author keywords

DiagnosticsNeuroblastomaOpsoclonus myoclonus ataxia syndromePositron emission tomography computed tomography

Substances

Fluorodeoxyglucose F18Radiopharmaceuticals

Authors and institutions

  • Department of Nuclear Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.
  • Department of Surgical Oncology, Beijing Children's Hospital, Beijing, China.
  • Department of Neurology, Beijing Children's Hospital, Beijing, China.
  • Department of Thoracic Surgery and Surgical Oncology, Children's Hospital, Capital Institute of Pediatrics, Beijing, China.
  • Department of Nuclear Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China. yangjigang@ccmu.edu.cn.

ORCID profiles: Lijuan Feng, Jigang Yang

Funding

  • National Natural Science Foundation of China

Cite

APA

Feng, L., Yang, S., Lin, Y., Li, J., Cao, Z., Zheng, Q., Wang, H., & Yang, J. (2024). Diagnostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging in pediatric opsoclonus myoclonus ataxia syndrome presenting with neuroblastoma. Pediatric Radiology. https://doi.org/10.1007/s00247-024-05921-9

Vancouver

Feng L, Yang S, Lin Y, Li J, Cao Z, Zheng Q, et al. Diagnostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging in pediatric opsoclonus myoclonus ataxia syndrome presenting with neuroblastoma. Pediatric Radiology. 2024. doi:10.1007/s00247-024-05921-9

BibTeX
@article{Feng2024,
  author = {Feng, Lijuan and Yang, Shen and Lin, Yu and Li, Jiuwei and Cao, Zhenhua and Zheng, Qipeng and Wang, Huanmin and Yang, Jigang},
  title = {Diagnostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging in pediatric opsoclonus myoclonus ataxia syndrome presenting with neuroblastoma},
  journal = {Pediatric Radiology},
  year = {2024},
  doi = {10.1007/s00247-024-05921-9}
}
Start for free →